194 related articles for article (PubMed ID: 19436204)
1. Morbidity and mortality in the antiphospholipid syndrome.
Espinosa G; Cervera R
Curr Opin Pulm Med; 2009 Sep; 15(5):413-7. PubMed ID: 19436204
[TBL] [Abstract][Full Text] [Related]
2. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients.
Cervera R; Khamashta MA; Shoenfeld Y; Camps MT; Jacobsen S; Kiss E; Zeher MM; Tincani A; Kontopoulou-Griva I; Galeazzi M; Bellisai F; Meroni PL; Derksen RH; de Groot PG; Gromnica-Ihle E; Baleva M; Mosca M; Bombardieri S; Houssiau F; Gris JC; Quéré I; Hachulla E; Vasconcelos C; Roch B; Fernández-Nebro A; Piette JC; Espinosa G; Bucciarelli S; Pisoni CN; Bertolaccini ML; Boffa MC; Hughes GR;
Ann Rheum Dis; 2009 Sep; 68(9):1428-32. PubMed ID: 18801761
[TBL] [Abstract][Full Text] [Related]
3. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors.
Espinosa G; Bucciarelli S; Asherson RA; Cervera R
Semin Thromb Hemost; 2008 Apr; 34(3):290-4. PubMed ID: 18720310
[TBL] [Abstract][Full Text] [Related]
4. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality.
Espinosa G; Cervera R
Nat Rev Rheumatol; 2010 May; 6(5):296-300. PubMed ID: 20386563
[TBL] [Abstract][Full Text] [Related]
5. Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS.
Cervera R; Espinosa G; Cordero A; Oltra MR; Unzurrunzaga A; Rossiñol T; Plaza J; Bucciarelli S; Ramos-Casals M; Ingelmo M; Asherson RA; Font J;
Semin Arthritis Rheum; 2007 Apr; 36(5):287-96. PubMed ID: 17207521
[TBL] [Abstract][Full Text] [Related]
6. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.
Cervera R; Serrano R; Pons-Estel GJ; Ceberio-Hualde L; Shoenfeld Y; de Ramón E; Buonaiuto V; Jacobsen S; Zeher MM; Tarr T; Tincani A; Taglietti M; Theodossiades G; Nomikou E; Galeazzi M; Bellisai F; Meroni PL; Derksen RH; de Groot PG; Baleva M; Mosca M; Bombardieri S; Houssiau F; Gris JC; Quéré I; Hachulla E; Vasconcelos C; Fernández-Nebro A; Haro M; Amoura Z; Miyara M; Tektonidou M; Espinosa G; Bertolaccini ML; Khamashta MA;
Ann Rheum Dis; 2015 Jun; 74(6):1011-8. PubMed ID: 24464962
[TBL] [Abstract][Full Text] [Related]
7. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors.
Bucciarelli S; Cervera R; Espinosa G; Gómez-Puerta JA; Ramos-Casals M; Font J
Autoimmun Rev; 2006 Dec; 6(2):72-5. PubMed ID: 17138246
[TBL] [Abstract][Full Text] [Related]
8. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients.
Bucciarelli S; Espinosa G; Cervera R; Erkan D; Gómez-Puerta JA; Ramos-Casals M; Font J; Asherson RA;
Arthritis Rheum; 2006 Aug; 54(8):2568-76. PubMed ID: 16868979
[TBL] [Abstract][Full Text] [Related]
9. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.
Cervera R; Asherson RA; Acevedo ML; Gómez-Puerta JA; Espinosa G; De La Red G; Gil V; Ramos-Casals M; García-Carrasco M; Ingelmo M; Font J
Ann Rheum Dis; 2004 Oct; 63(10):1312-7. PubMed ID: 15361392
[TBL] [Abstract][Full Text] [Related]
10. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".
Cervera R; Bucciarelli S; Plasín MA; Gómez-Puerta JA; Plaza J; Pons-Estel G; Shoenfeld Y; Ingelmo M; Espinos G;
J Autoimmun; 2009; 32(3-4):240-5. PubMed ID: 19324520
[TBL] [Abstract][Full Text] [Related]
11. New subsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic antiphospholipid syndromes ("MAPS").
Asherson RA
Autoimmun Rev; 2006 Dec; 6(2):76-80. PubMed ID: 17138247
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome.
Gómez-Puerta JA; Cervera R; Espinosa G; Bucciarelli S; Font J
Autoimmun Rev; 2006 Dec; 6(2):85-8. PubMed ID: 17138249
[TBL] [Abstract][Full Text] [Related]
13. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome.
Cervera R; Font J; Gómez-Puerta JA; Espinosa G; Cucho M; Bucciarelli S; Ramos-Casals M; Ingelmo M; Piette JC; Shoenfeld Y; Asherson RA;
Ann Rheum Dis; 2005 Aug; 64(8):1205-9. PubMed ID: 15708888
[TBL] [Abstract][Full Text] [Related]
14. Stroke and antiphospholipid syndrome: the treatment debate.
Ruiz-Irastorza G; Khamashta MA
Rheumatology (Oxford); 2005 Aug; 44(8):971-4. PubMed ID: 15840602
[TBL] [Abstract][Full Text] [Related]
15. The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome.
Bucciarelli S; Espinosa G; Cervera R
Lupus; 2009 Sep; 18(10):905-12. PubMed ID: 19671791
[TBL] [Abstract][Full Text] [Related]
16. [Antiphospholipid antibody syndrome].
Chakoutio V; Ries F
Bull Soc Sci Med Grand Duche Luxemb; 2009; (1):27-43. PubMed ID: 19514174
[TBL] [Abstract][Full Text] [Related]
17. Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome.
Espinosa G; Bucciarelli S; Cervera R; Gómez-Puerta JA; Font J
Autoimmun Rev; 2006 Dec; 6(2):68-71. PubMed ID: 17138245
[TBL] [Abstract][Full Text] [Related]
18. Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment.
Asherson RA; Espinosa G; Cervera R; Font J; Reverter JC
J Clin Rheumatol; 2002 Jun; 8(3):157-65. PubMed ID: 17041346
[TBL] [Abstract][Full Text] [Related]
19. The Ped-APS Registry: the antiphospholipid syndrome in childhood.
Avcin T; Cimaz R; Rozman B;
Lupus; 2009 Sep; 18(10):894-9. PubMed ID: 19671789
[TBL] [Abstract][Full Text] [Related]
20. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome.
Uthman I; Shamseddine A; Taher A
Transfus Apher Sci; 2005 Aug; 33(1):11-7. PubMed ID: 15951243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
